From Liston Street Pulse:
Shares of Cardiome Pharma Corp. (CRME), a research-based biopharmaceutical company, have surged in trading today after the company announced publication of positive data from a study comparing vernakalant intravenous (IV) to oral propafenone and oral flecainide. CRME shares struck a 52-week high of $3.95. At last check, the stock was […]
The post Cardiome Pharma Surges on Positive Data appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015